Urgent Lipoprotein(a) — Lp(a) + Treatment Roadmap

Cardiovascular · Lipids · Genetics · Risk Factor · Therapeutics

Baseline Risk at 800+ mg/L

Lp(a) is an independent, causal, and genetic risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease. Elevated Lp(a) affects approximately 20% of the global population. Levels are predominantly genetically determined and remain largely stable throughout life.

At levels above 350 mg/L (~70 mg/dL), risk is significantly elevated. At 800+ mg/L, this is approximately 3x the upper reference limit and confers high lifetime cardiovascular risk. Lp(a) promotes atherosclerosis through:

• Cholesterol deposition in arterial walls (via apoB-100 component)
• Prothrombotic effects (structural similarity to plasminogen inhibits fibrinolysis)
• Pro-inflammatory effects (carries oxidized phospholipids)
• Promotes calcific aortic valve disease

Statin Paradox

Statins increase Lp(a) by ~10-20% in most patients, though the effect is inconsistent — some studies show neutral effect on Lp(a). For those affected, however, the net clinical benefit remains positive: LDL-C reduction outweighs the modest Lp(a) increase, and statins have pleiotropic effects (anti-inflammatory, plaque stabilization). Continuing atorvastatin is correct.

Treatment Roadmap — Four Options Compared

A) Continue Statin Alone (Current)

Floor strategy. Atorvastatin provides LDL-C reduction and pleiotropy but does NOT lower Lp(a). Insufficient alone given 800+ mg/L.

B) Add Ezetimibe

Adds ~15-20% LDL-C reduction but has no meaningful effect on Lp(a). Useful for LDL-C lowering only.

C) Add PCSK9 Inhibitor Now

Available: Yes — Repatha (evolocumab) and Praluent (alirocumab) available in SE Asia.

• Lp(a) reduction: ~27% (FOURIER trial, meta-analyses confirm 20-30%)
• Also adds 50-60% LDL-C reduction on top of statin
• Cost SE Asia: ~$200-600/month private
• Administration: Subcutaneous injection every 2-4 weeks
• Safety: Excellent (FOURIER: >27,000 patients; ODYSSEY)

Verdict: Best currently available option.

D) Wait for Lp(a)-Specific Therapies

• Pelacarsen (Novartis/Ionis): ASO. HORIZON phase 3 results H1 2026. Regulatory submissions H2 2026. ~80% reduction in phase 2.
• Olpasiran (Amgen): siRNA. OCEAN(a)-DOSE phase 2 showed >95% placebo-adjusted reduction. Phase 3 ongoing.
• Muvalaplin (Kyowa Kirin): Oral pill. KRAKEN phase 2 (233 pts, Asia/Europe/Brazil/US/aus: Dec 2022-Jun 2024): up to 85.5% reduction in 12 weeks. Phase 3 ongoing.
• SE Asia access: FDA 2026-2027 → regional approval lags 1-3 years → realistic access 2027-2029

Key Takeaways

1. Adding PCSK9 inhibitor now is the best option: 27% Lp(a) + 60% LDL reduction available today
2. Monitor HORIZON results (H1 2026) and muvalaplin phase 3 for oral option
3. SE Asia access to Lp(a)-specific therapies: estimated 2027-2029
4. Smoking cessation remains the single most impactful modifiable risk factor

Urgent Combined ASCVD Risk Quantification

Cardiovascular · Risk Assessment · Lp(a) · HDL · Smoking · ApoB

The Risk Calculator Problem

The standard ASCVD risk calculator (Pooled Cohort Equations, PCE) does NOT include Lp(a). Neither does the newer AHA PREVENT 2023 equation — Lp(a) is explicitly excluded despite being independently associated with ASCVD risk. This means every standard risk score significantly underestimates actual risk for this profile.

Multiple 2024-2025 studies have tested adding Lp(a) to PREVENT and PCE equations. Adding Lp(a) levels improves net reclassification improvement (NRI) and C-statistic, but the effect size is modest at the population level. However, for individuals with very high Lp(a) like 800+ mg/L, the underestimation is substantial.

Relative Risk Multipliers (Evidence-Based)

From large pooled cohort analyses (US prospective studies, UK Biobank, JUPITER/ARIC cohorts):

• Lp(a) >70 mg/dL (~350 mg/L): ~1.5-2.0x relative risk for ASCVD vs normal Lp(a)
• Lp(a) >100 mg/dL (~500 mg/L): ~2.0-2.5x relative risk
• At 800+ mg/L (~160 mg/dL): ~2.5-3.0x relative risk for ASCVD vs normal Lp(a)
• Smoking alone: ~2.0-3.0x relative risk for MI
• Lp(a) + smoking interaction: The multiplicative effect is additive-to-multiplicative. A 2024 analysis of 12 risk factors found that Lp(a) and smoking have an interaction effect on a multiplicative scale. Combined: ~4-6x relative risk compared to non-smoker with normal Lp(a)

Protective Factors in This Profile

Estimated 10-Year ASCVD Risk

Using PCE for a 51M smoker without treatment: ~7-10% (intermediate risk). Adding Lp(a) as a risk enhancer (per 2024 NLA and EAS guidelines), this shifts upward substantially. Expert consensus suggests that with Lp(a) >75th percentile + smoking, the effective 10-year risk may be ~15-25% — borderline high-risk territory despite favorable ApoB and triglycerides.

Key Takeaways

1. PCE and PREVENT calculators significantly underestimate risk — Lp(a) not included in either
2. Effective risk is likely 2-3x higher than calculator output due to very high Lp(a) + smoking
3. Low ApoB (63.9) and very low triglycerides are genuinely protective and should not be ignored
4. The single biggest gap: smoking — quitting would reduce risk by approximately 30-50%

Urgent Imaging Thresholds — CCTA/CAC/Echo

Cardiovascular · Screening · Coronary Artery Disease · Aortic Valve

Evidence for Imaging in High-Lp(a) Asymptomatic Patients

2024 ACC/AHA lipid management guidelines now recommend selective use of coronary calcium scoring and testing Lp(a) and ApoB in all adults once in their lifetime. The guidelines recognize that Lp(a) patients have "invisible" residual risk not captured by clinical scores.

Multiple 2024-2025 studies specifically examined the combination of Lp(a) and coronary imaging:

• Cross-sectional studies show Lp(a) is more strongly associated with noncalcified and mixed plaque than with calcified plaque. This means CAC scoring alone may miss early disease in high-Lp(a) patients
• Asymptomatic adults with elevated Lp(a) have increased odds of coronary plaque and multiple high-risk plaque features on coronary CT angiography (CCTA)
• ESC/EAS 2022 focused update: CAC scoring recommended for risk stratification in intermediate-risk individuals with risk enhancers like elevated Lp(a)

Guidelines vs Specialist Practice — Important Gap

ESC/AHA/ACC guidelines: Test Lp(a) once in a lifetime. Use as risk enhancer. Do NOT recommend automatic CAC/CCTA for asymptomatic high-Lp(a) patients alone. In Norway's public system, Lp(a) alone does not qualify for cardiac imaging referral — you need symptoms, abnormal ECG, or high SCORE2 + additional factors.

Preventive cardiology specialists: For Lp(a) >50-80 mg/dL (~500-800+ mg/L) in 40-60yo patients, increasingly recommend baseline CAC to "anchor" risk and justify treatment intensity. Many use CCTA as preferred first-line since it captures noncalcified plaque that CAC misses.

For this profile (Lp(a) 838+ mg/L): Even if CAC = 0, specialists still recommend aggressive lipid lowering because Lp(a) drives both atherosclerosis AND aortic valve stenosis (separate mechanisms). The imaging result changes HOW aggressively to treat, not WHETHER to treat.

CAC vs CCTA for high Lp(a): CAC alone is limited here — a zero score wouldn't change the need for aggressive treatment, and a positive score just confirms the Lp(a) risk. CCTA with AI-QCT quantifies soft plaque volume, giving a real baseline you can track over time. Bangkok Bumrungrad CCTA: ~12,000 THB (~$340 USD, per patient reports).

Recommended Imaging Plan

1. Coronary Artery Calcium Score (CAC) — Quick Screen

• Why: Quick (5 min), low radiation (~1 mSv), low cost (~$50-100 in Thailand), well-validated for risk stratification
• Interpretation: CAC = 0 → very low near-term event risk even with high Lp(a). CAC >0 → presence of subclinical atherosclerosis. CAC >100 → high risk. CAC >400 → very high risk
• Critical limitation: Lp(a) promotes noncalcified plaque which CAC may not detect — a CAC of 0 does NOT guarantee clean arteries in high-Lp(a) patients. CAC alone cannot capture soft plaque, which is the primary form Lp(a) deposits.
• For Lp(a) 838+ mg/L: CAC=0 doesn't change the need for aggressive treatment (statins, possibly PCSK9i) because of aortic valve and thrombogenic risk independent of plaque. CCTA is preferred if accessible.

2. Coronary CT Angiography (CCTA) — Strongly Consider as First-Line

• Why: Directly visualizes both calcified and noncalcified plaque, can identify high-risk plaque features (thin-cap fibroatheroma, positive remodeling, low-attenuation plaque)
• Studies show: Lp(a) patients have more noncalcified/high-risk plaque features even with low CAC scores
• Important for Lp(a) 838+: CAC misses noncalcified plaque, so CAC=0 is much less reassuring here. CCTA sees everything CAC misses plus more — plaque composition, volume, and stenosis severity. For Lp(a) this high, CCTA is the better first-line test.
• Cost: ~$340 USD at Bumrungrad Bangkok (12,000 THB, confirmed). RPPH capability unconfirmed.
• Given the April pain episode (chest/epigastric pain + sweating + left arm symptoms = red flag), CCTA may be warranted regardless of CAC score

3. Echocardiography for Aortic Valve

• Why: Lp(a) is a causal risk factor for calcific aortic valve disease (CAVD). Elevated Lp(a) independently predicts aortic valve calcification and stenosis
• 2026 EHJ study (DOI: 10.1093/ehjci/jeag051): combined Lp(a) and AI-CCTA can unmask 'invisible' residual cardiovascular risk beyond CAC score
• Recommended: One baseline echo to assess aortic valve status, then repeat every 2-3 years

Recommended Imaging Plan

Key Takeaways

1. CAC = 0 is very reassuring but less reassuring in high-Lp(a) than average risk (noncalcified plaque blind spot)
2. CCTA is the preferred imaging modality if CAC >0 or if symptoms recur — it detects noncalcified plaque
3. The April pain episode with left arm involvement is a red flag — imaging should be prioritized
4. Echocardiography for baseline aortic valve assessment is warranted given Lp(a) at 800+ mg/L

Important CT Scan Preventive Screening

Screening · Cardiovascular · Pulmonary · CEA · Lp(a)

Why CT Scans Matter for This Profile

Blood markers (LDL 1.97, ApoB 63.9, HDL 2.53) look good on paper, but Lp(a) at 838 mg/L drives plaque deposition in ways these markers don't capture. Lp(a) is independently atherogenic and prothrombotic. Blood tests measure risk factors; CT scans measure actual disease. A CT scan bridges the gap between "risk profile" and "actual damage."

Compounding factors: smoking history (20 cig/day, on/off 7-8 yrs), April 2026 episode (sudden intense stomach pain, dizziness, sweating, left-arm cramping), CEA elevation (8.68 -> 5.20), on Atorvastatin 20mg (reduced from 40mg Oct 2025).

1. Coronary Artery Calcium (CAC) Scan — Priority 1

A specialized non-contrast CT of the heart quantifying calcified plaque (Agatston score). ~1 mSv. Takes 5 min. No contrast, no fasting, no prep. Cost: ~$75-250 (Thailand).

Score Interpretation & Action

Limitation: Lp(a) promotes noncalcified plaque which CAC may not detect. A CAC of 0 doesn't guarantee clean arteries in high-Lp(a) patients — but still provides meaningful risk stratification.

2. Low-Dose Chest CT (LDCT) — Priority 2

Targeted low-radiation chest CT for early lung cancer detection. ~1.5 mSv.

• Smoking history: ~20 cigarettes/day during heavy periods over 7-8 years. If pack-years approach 20+, qualifies per USPSTF Grade B.
• CEA elevation context: CEA was 8.68 -> 6.59 -> 5.20. Colonoscopy found diverticulosis but no cancer. CEA can be elevated from smoking (most likely), diverticular inflammation, or lung pathology. A baseline LDCT helps rule out pulmonary source.
• If clear: Establishes baseline. Future comparison point.
• If nodules found: Follow Fleischner criteria. Nodule >8mm triggers PET-CT or biopsy.

3. CCTA — Second-Line or Preferred First-Line (see note)

CT with IV contrast for detailed 3D coronary stenosis mapping. 128+ slice scanner required with ECG gating. ~5-12 mSv.

• Why CCTA over CAC for this profile: Lp(a) promotes noncalcified plaque which CAC cannot detect. CCTA sees calcified + noncalcified plaque, measures plaque volume/composition, and can identify high-risk features (thin-cap fibroatheroma, positive remodeling). For Lp(a) >800 mg/L, CCTA provides vastly more actionable data than CAC alone.
• Consider as first-line if: April episode symptoms return, or if CCTA is available at reasonable cost (it is, in Bangkok at ~$340)
• Still second-line if: Cost or access is a constraint, CAC remains the most cost-efficient screening step
• Prep: fasting 4 hours, no caffeine/stimulants, regular heart rate needed, 10-second breath-hold per scan cycle

CAC tells you "plaque exists." CCTA tells you "there is a 60% narrowing in the LAD + 23 mm³ noncalcified plaque volume." The latter guides actual intervention decisions.

Important Nuance: CAC = 0 Does NOT Equal Zero Risk Here

With Lp(a) >838 mg/L, even a CAC score of 0 does not justify stopping aggressive lipid management. Reasons:

• Lp(a) drives noncalcified plaque — invisible to CAC Agatston scoring
• Lp(a) causes calcific aortic valve disease — entirely separate from coronary arteries, CAC doesn't scan this
• Lp(a) has prothrombotic effects — independent of plaque burden
• Specialists at your Lp(a) level recommend treating aggressively regardless of CAC result

The CAC result changes how aggressively to treat (statin dose, PCSK9i consideration), but not whether to treat.

4. CT Abdomen — NOT PRIORITY

Colonoscopy (Sept 2024) already clear for cancer. Calprotectin declining (141 -> 87). Stool occult blood NEGATIVE. CT abdomen adds minimal value. If CEA continues rising or new symptoms develop, reassess.

5. Full-Body Screening CT — DO NOT DO

Recommended against by USPSTF, ACR, American College of Physicians. High incidentaloma rate triggering invasive follow-ups. High radiation (~10-15 mSv). No mortality benefit in asymptomatic individuals.

Decision Tree

Step 1: CAC scan (priority)
  |
  |-- CAC = 0: Stay 20mg statin. Consider LDCT. Re-scan in 3-5 years.
  |-- CAC = 1-99: Bump to 40mg. Consider LDCT. Re-scan in 2-3 years.
  |-- CAC = 100-399: Cardiology referral. Consider CCTA. LDCT baseline.
  |-- CAC = 400+: Full cardiology workup. CCTA. Evaluate pelacarsen.
  |
Step 2: LDCT chest (baseline, regardless of CAC)
  |-- Clear: Baseline established
  |-- Nodules: Follow Fleischner criteria

Radiation Doses

Key Takeaway

CAC scan is the highest-value next diagnostic step. It's cheap, low-radiation, non-invasive, and the result directly changes statin dosing and cardiovascular management. At 51 with Lp(a) at 838 mg/L, the "normal" blood picture may be hiding real plaque. The April pain/episode context makes this even more relevant.

Important Eczema-Diverticular Disease Connection

Immunology · Skin · Gastrointestinal · Skin-Gut Axis · Microbiome

Core Question

Dag has chronic eczema (recurrent 1 week after stopping Locoid, worsened 2020, improved with vegan diet + probiotics) AND diverticular disease with bleeding history (Aug 2025). Are they connected through shared inflammation pathways?

Short Answer: Yes, They Share Mechanisms

Five lines of evidence converge:

1. Epidemiological -- eczema patients have higher IBD and diverticulitis risk
2. Causal (Mendelian Randomization) -- AD causes IBD (arrow flows skin -> gut)
3. Mechanistic -- skin-gut axis, shared Th2/Th17 pathways, mast cell activation
4. Pharmacological -- Upadacitinib (JAK inhibitor) treats both AD and IBD
5. Direct clinical evidence -- psoriasis increases diverticulitis risk 1.16x (PMID: 31039227)

Epidemiological Evidence

Skin-Gut Axis -- Mechanistic Pathways

• Gut dysbiosis -> leaky gut -> systemic inflammation -> eczema flare (Lipska 2026, PMID: 41897446): "AD may be a systemic disorder with both gut and skin manifestations, not purely a skin disease"
• SCFA depletion -- butyrate and propionate-producing bacteria are depleted in both AD and IBD. Dag's high-fiber vegetarian diet restores SCFA, which helps both organs
• Mast cell activation -- present in both skin and gut mucosa. Drives eczema itching AND gut inflammation/motility issues
• Shared cytokines -- Th2 (IL-4, IL-13, IL-31) for eczema; Th17 (IL-17, IL-23) for psoriasis. Both pathways affect gut inflammation
• Barrier dysfunction parallel -- skin filaggrin mutations (eczema) mirror gut tight junction disruption (diverticular). Alcohol is a major tight junction disruptor
• Upadacitinib treats both AD and IBD -- FDA-approved for both. JAK/STAT pathway is the common molecular target (PMID: 40875187)

What This Means for Dag

Observed in his own data:

• "This [daily vegetables] with combination of probiotics I believe, had a very positive effect on my eczema" -- this is the skin-gut axis in action
• Eczema flares return 1 week after stopping Locoid -- because systemic/gut inflammation persists
• Calprotectin elevated (87-141 ug/g) -- intestinal inflammation that shares mechanisms with skin inflammation
• Alcohol worsens both gut AND likely skin -- gut barrier disruption + systemic inflammation

The Connection Is Not "Eczema Causes Diverticular"

Instead, they share: (1) systemic Th2/Th17 dysregulation, (2) gut microbiome as common upstream driver, (3) barrier dysfunction in both organs, (4) diet as the common treatment lever. The MR study suggests skin -> gut is the causal direction, meaning chronic skin inflammation likely contributes to subclinical gut inflammation.

Key Implications

The Corticosteroid Rebound Cycle

The 1-week recurrence after stopping Locoid is significant. Topical steroids suppress skin inflammation but don't treat the underlying systemic or gut-level inflammation. The Taiwan study (PMID: 41858144) found higher IBD risk in AD patients NOT using corticosteroids, suggesting steroids may also suppress subclinical gut inflammation. When Dag stops Locoid, the skin rebounds because the systemic driver persists.

Potential Tests

• Serum tryptase -- mast cell activation marker (skin + gut)
• Zonulin -- intestinal permeability marker (leaky gut)
• Fecal SCFA profile -- butyrate/propionate levels
• Dermatology follow-up -- confirm eczema vs psoriasis vs overlap (treatment differs)

Key Takeaway

Dag's instinct that fixing the gut helps eczema is evidence-based. The skin-gut axis is well-established in the literature. The gut microbiome is the common upstream driver -- healing it through fiber, probiotics, and Omega-3 should improve both eczema and diverticular outcomes. The recurring eczema after stopping Locoid suggests the systemic inflammation isn't being fully addressed by topical treatment alone.

Urgent Thrombocytosis and Combined Thrombotic Risk

Hematology · Platelets · Thrombosis · Lp(a) · JAK2

Profile: Chronically Elevated Platelets

Platelets 439-520 (ref max 348) in every single test since 2021. 511 (2022) -> 439 (2024) -> 520 (Aug 2025) -> 439 (Dec 2025). Combined with Lp(a) 838 mg/L and smoking history.

Leading Diagnosis: Reactive Thrombocytosis

Multiple converging reactive drivers fully explain the elevation:

• Iron deficiency: Ferritin declining 93 -> 35. Iron deficiency impairs erythropoiesis, leading to elevated EPO/TPO cross-stimulation of megakaryocytes. Well-documented cause of reactive thrombocytosis.
• Post-GI bleeding: Aug 2025 diverticular bleed triggered compensatory marrow response.
• Chronic inflammation: Elevated calprotectin (87-141), IL-6 (5.97), IgE (144-375), ESR (22). IL-6 directly stimulates hepatic TPO production.

Why Essential Thrombocythemia (ET) Is Less Likely

• Count 430-520 is characteristic of reactive thrombocytosis. ET typically >600-800, often >1,000.
• No microvascular symptoms (no erythromelalgia, TIAs, or unexplained thrombosis).
• However: platelets elevated >3 years — persistence is noteworthy.

Synergistic Thrombotic Risk: The Triad

Synergy: Endothelial damage (smoking) → rapid platelet adhesion (thrombocytosis) → impaired clot dissolution (Lp(a)) → stable, occlusive thrombi form more easily and persist longer.

Management Recommendations

1. Correct iron deficiency first — oral or IV iron, re-check platelets + ferritin at 8-12 weeks
2. If platelets normalize with ferritin >50-100: confirmed reactive, case closed
3. If platelets remain >450 despite ferritin normalization: JAK2 V617F + CALR/MPL testing
4. JAK2 V617F can be tested now — inexpensive blood test, positive result changes clinical interpretation regardless
5. Aspirin contraindicated due to diverticular bleed history (2-4x rebleeding risk)
6. Atorvastatin provides mild antiplatelet effect — reduces P-selectin, aggregation
7. Absolute smoking cessation is highest-ROI intervention

Important TSH Thyroid Trend and Lp(a)

Endocrinology · Thyroid · Lp(a) · Statin Interaction

The Critical Trend

TSH: 1.5 (2015) -> 1.4 (2018) -> 2.0 (2024-08) -> 2.65 (2025-10) -> 2.82 (2025-11) -> 3.61 (2025-12). Ref: 0.20-4.0. Free T4: 15.8-18.0 pmol/L, consistently normal. On Atorvastatin, reduced 40mg -> 20mg Oct 2025.

Key Finding: Rate of TSH Rise Is Too Fast for Age Alone

Normal age-related drift: ~0.1-0.2 mU/L per decade. Dag's rate: ~0.27 per year since 2024. This strongly suggests pathology beyond normal aging.

Lp(a)-Thyroid Link: A Self-Reinforcing Loop

Hypothyroidism significantly increases Lp(a) levels — even subclinical (TSH 3.0-4.5) raises Lp(a) by 10-30%. Mechanism: reduced hepatic Lp(a) clearance. Treating hypothyroidism lowers Lp(a) by 15-40%.

The loop: statins -> may raise TSH -> worsening subclinical hypothyroidism -> higher Lp(a) -> need statins. If TSH continues rising, Dag's already critical Lp(a) 838 could increase further.

Atorvastatin Contribution

Statins can raise TSH (PMID: 24974574). The Oct 2025 dose reduction (40mg -> 20mg) may partially reverse this. Next TSH reading is critical — if TSH stabilizes or drops, statin contribution confirmed; if continues rising, suggests independent pathology.

Recommendations

• TSH + Free T4 + TPO antibodies at next blood draw (~$7-15 at Biomed)
• If TPO Ab positive: monitor TSH every 3-6 months (4.4% annual progression risk)
• If TSH crosses 4.0: consider levothyroxine 25-50mcg — could lower Lp(a) by 15-40%
• If TSH stabilizes after statin reduction: confirms statin-TSH interaction

Important Inflammatory-Thrombotic Axis

ESR · Fibrinogen · CRP · Platelets · Calprotectin · IgE

The Cluster: Chronic Inflammation Driving Thrombotic Risk

Key Pattern: ESR > CRP = Chronic Inflammation

ESR at 22 with CRP at 2.89 (both slightly elevated) is characteristic of chronic, low-grade inflammation — not acute flare. This aligns with persistent calprotectin (gut) + chronic eczema (skin).

Fibrinogen at 3.5 — Independently Prothrombotic

Every 1 g/L increase in fibrinogen ≈ 1.5x CV risk. At 3.5 vs "low normal" 2.0: roughly 30-40% increased baseline thrombotic risk from fibrinogen alone. Fibrinogen increases blood viscosity too.

The Immunothrombotic Pathway

Gut inflammation (diverticular) + skin inflammation (eczema) -> IL-6 production -> drives both fibrinogen (clotting substrate) and TPO (platelet production) -> creates systemic prothrombotic state. Combined with Lp(a)-driven fibrinolysis inhibition = clots form more easily and dissolve more slowly.

Multi-Source Inflammation

Even if gut inflammation resolves (calprotectin normalizes), systemic inflammation from eczema + metabolic factors (Lp(a), fibrinogen) persists. Dag has at least 3 independent inflammation sources: gut, skin, and metabolic (Lp(a)).

Monitor Calcium-PTH-Vitamin D Axis

Calcium · PTH · Vitamin D · Vitamin K2 · Vascular Calcification

PTH-Vitamin D Story: Secondary Hyperparathyroidism Resolved

2022-10: PTH was 11.9 (ref max 8.4) with Vitamin D at 67 nmol/L (insufficient). Classic secondary hyperparathyroidism — parathyroid overcompensating for low Vitamin D.

After D3+K2 supplementation: Vitamin D corrected to 98.7, PTH normalized to 4.4. Confirmed the high PTH was secondary, not primary.

Calcium at Upper Limit: Constitutional or Concerning?

Calcium 2.50 (ref 2.15-2.51) has been consistently at 2.49-2.50 since 2018 — before D3 supplementation started. This suggests constitutional high-normal calcium, not D3-induced hypercalcemia. Albumin is also slightly elevated at 48 (ref 36-47), contributing to higher total calcium.

Why This Matters for Lp(a) 838

Lp(a) promotes aortic valve calcification and arterial calcification. The risk equation:

Vitamin K2 is arguably the most critical supplement for Dag — without adequate K2, the combination of high Lp(a) + high calcium + D3 could accelerate vascular calcification.

Recommendations

• Re-check K2 blood level — the 0.2 µg/L value is from 2019, BEFORE D3+K2 supplementation. Need to verify the supplement is working.
• Ensure K2 MK-7 ≥90 mcg/day, consider 180-200 mcg given Lp(a) at 838
• Ionized calcium test for more accurate assessment
• Aortic valve echo — baseline for calcification given Lp(a) 838

Urgent Diverticular Disease

Gastrointestinal · Colon · Inflammation · Bleeding

Diagnosis: K57.3 — Diverticular disease of colon without perforation or abscess
"Spredte små divertikler fra høyre fleksur til kolon sigmoideum"
Bleeding episode: August 2025. No rebleeding since.

Fiber and Diet — Paradigm Shift

Historically, patients with diverticulosis were told to avoid nuts, seeds, and popcorn. This advice has been almost entirely reversed by modern evidence.

• High fiber intake is protective against diverticulitis and hospitalization. Protective effects from fruits and cereal fiber specifically. (Carabotti et al., 2021, PMID: 33919755)
• A 2012 large cohort study (Strate et al., NEJM): higher intake of nuts, corn, and popcorn was associated with LOWER risk of diverticulitis
• Recent umbrella review of 17+ million individuals confirms dietary fiber has broadly positive health impacts, including for diverticular disease (PMID: 40651334)

The low-fiber approach immediately after a bleed is still reasonable as a short-term measure (1-2 weeks). Gradual reintroduction to normal/high-fiber diet is the correct long-term strategy.

Post-Bleeding Management

• Most cases (75-80%) resolve spontaneously
• Rebleeding risk after first episode: approximately 10-40% (highest in first year)
• 7+ months without rebleeding is reassuring
• Fecal occult blood testing is appropriate for monitoring — negative result is reassuring

Exercise and Diverticular Risk

Regular physical activity and exercise are protective against diverticular disease complications. Vigorous physical activity associated with reduced risk of diverticulitis and diverticular bleeding. No evidence that running or jogging specifically increases diverticular bleeding risk. Continue jogging; it is likely protective overall.

Alcohol and Gut Health

2026 systematic review and meta-analysis of 62 studies (566,903 patients): Alcohol associated with increased diverticulosis risk (OR: 1.41). No significant association between alcohol and diverticular bleeding or diverticulitis specifically. Alcohol can affect gut motility, mucosal integrity, and the microbiome.

Smoking and Diverticular Disease

• Smoking increased risk of diverticulosis (OR: 1.36)
• Smoking increased risk of diverticulitis (OR: 1.59)
• Smoking increased risk of diverticular bleeding (OR: 1.51)
• Ex-smokers also showed increased risk vs never-smokers (OR: 1.31)

Rebleeding Risk Factors

Known risk factors: prior bleeding, right-sided diverticula, NSAID/aspirin use, anticoagulants, number of diverticula, older age, angiodysplasia coexistence, obesity, hypertension. Right-sided diverticula present in this case (span from right flexure to sigmoid) = higher rebleeding risk.

Calprotectin Monitoring

FC is a sensitive marker of intestinal inflammation. A declining trend is the most important pattern — direction matters more than absolute value. FC correlates with response to therapy — values decrease in responders, remain elevated in non-responders. If calprotectin continues to trend toward normal, gut mucosa is healing.

Key Takeaways for This Profile

1. Current diet approach (full fiber reintroduction) is evidence-based and correct
2. 7+ months without rebleeding + negative fecal occult blood = reassuring trajectory
3. Calprotectin trending down (141 → 87) suggests resolving inflammation — continue monitoring
4. Exercise is protective, not harmful. Jogging should continue
5. Alcohol reduction is well-founded based on evidence + personal experience
6. Multi-strain probiotics are evidence-aligned for diverticular disease
7. Smoking cessation is one of strongest modifiable risk factors for diverticular complications
8. Repeat colonoscopy not urgently needed; follow standard CRC screening schedule unless symptoms change

PMIDs: 33919755, 40651334, 39976023, 40012838, 41760075, 30631757, 22572679

Urgent Diverticular Surveillance & Rebleeding Prevention

Gastrointestinal · Surveillance · Colonoscopy · FIT · Prevention

Post-Bleed Surveillance Protocol

After a significant diverticular hemorrhage (Aug 2025 in this case), the following surveillance strategy is evidence-based:

Colonoscopy Timing

• During acute bleed: Colonoscopy within 24 hours is recommended (after bowel prep) — this was presumably done at the time of bleeding, confirming diverticular disease from right flexure to sigmoid
• After resolution: Guidelines recommend follow-up colonoscopy to rule out other pathology if not done during the acute event. If a full colonoscopy was done during the bleeding episode (as documented), repeat is not needed for 5-10 years unless symptoms change or FIT is positive
• Exception: If the initial exam was incomplete or only sigmoidoscopy, or if there is concern about missed lesions, repeat should be done sooner (1-2 years)

FIT/FITB Monitoring

FIT (faecal immunochemical test) detects human hemoglobin specifically from the colon, unlike guaiac FOBT which has dietary false positives.

• Frequency: Every 6 months given diverticular bleeding history + declining ferritin
• Positive FIT → immediate GI referral for repeat colonoscopy or CT angiography
• Negative FIT → reassuring, continue 6-monthly monitoring
• Current FOBT was NEGATIVE as of Dec 2025 — this is reassuring but was 4+ months ago at the time of this report

Rebleeding Prevention Strategies

Medications to Avoid

• NSAIDs (ibuprofen, naproxen): Increase diverticular bleeding risk (OR 1.5-2.0). Acetaminophen/paracetamol is preferred for pain
• Aspirin: See Antithrombotic Strategy section — contraindicated in this profile
• Anticoagulants: Only if absolutely indicated; increased rebleeding risk

Specific Rebleeding Risk Factors for This Profile

Key Takeaways

1. If the Aug 2025 colonoscopy was complete (right colon examined), repeat not needed for 5-10 years unless FIT positive or symptoms change
2. FIT every 6 months for surveillance — quick, cheap, and specific
3. Right-sided diverticula = higher rebleed risk profile
4. Avoid NSAIDs completely; use acetaminophen for pain
5. Continue smoking cessation — smoking increases diverticular bleed risk by 51%

Important HDL Cholesterol

Lipids · Cardiovascular · Metabolic Health

HDL U-Shaped Mortality Curve

The belief that "higher HDL is always better" has been thoroughly overturned. Current evidence demonstrates a J-shaped or U-shaped relationship between HDL-C levels and both all-cause and cardiovascular mortality.

• Optimal HDL-C for cardiovascular mortality is approximately 1.3-2.1 mmol/L (50-80 mg/dL). Note: a recent meta-analysis found very high HDL is NOT associated with increased all-cause mortality — the U-shape is specific to cardiovascular mortality.
• Above 2.3 mmol/L (~90 mg/dL), cardiovascular mortality curve begins to turn upward (all-cause mortality not consistently elevated)
• Above 2.6 mmol/L (~100 mg/dL), cardiovascular mortality risk becomes more clearly elevated

HDL + Low Triglycerides Profile

HDL of 2.53 mmol/L combined with triglycerides of 0.62-1.08 mmol/L (well below upper limit). High HDL + low triglycerides is generally the most favorable lipid phenotype, reflecting excellent insulin sensitivity and good metabolic health. The HDL/DG ratio is one of the most predictive lipid ratios for cardiovascular risk. Low triglycerides independently protective.

HDL and Lp(a) Interaction

No offsetting effect: Lp(a) promotes atherosclerosis through prothrombotic and oxidized phospholipid mechanisms that HDL's reverse cholesterol transport does not counteract. Lp(a) is pro-atherogenic and pro-thrombotic regardless of HDL-C level. Do not let very high HDL-C provide false reassurance about Lp(a) risk.

HDL Function vs Quantity

The distinction between HDL quantity (HDL-C level) and HDL function has become one of the most important paradigm shifts in cardiovascular risk assessment. Cholesterol efflux capacity (CEC) — ability of HDL to accept and transport cholesterol from arterial plaques — is inversely associated with CV events, independent of HDL-C levels. HDL-raising drugs (niacin, CETP inhibitors) all raised HDL-C 50-300% but failed to improve outcomes.

Key Takeaways for This Profile

1. HDL at 2.53 mmol/L is approaching the U-shaped curve inflection point (~2.3-2.6 mmol/L)
2. Not yet at level where studies consistently show increased mortality (> 2.6 mmol/L)
3. Low triglycerides + well-controlled LDL + excellent HbA1c all suggest benign cause
4. HDL function matters more than quantity — function testing not widely available
5. High HDL does NOT offset Lp(a) risk — these factors operate independently
6. Monitor HDL trend — if it exceeds 2.6 mmol/L, consider further investigation

PMIDs: 41618310, 41284745, 40443511, 35583863, 40858201, 41618471

Important Antithrombotic Strategy with High Bleeding Risk

Cardiovascular · Antithrombotics · Lp(a) · GI Bleeding · Primary Prevention

The Clinical Tension

High Lp(a) is prothrombotic, which has led some researchers to suggest aspirin for primary prevention. However, the patient has a history of diverticular hemorrhage (K57.3, Aug 2025), which is a strong contraindication.

Aspirin + Lp(a) — The Evidence

Secondary analyses of clinical trials using genetic instruments have suggested that individuals with genetically high Lp(a) may derive greater cardiovascular benefit from aspirin in primary prevention. One analysis found an absolute risk reduction of 2.69% for major cardiovascular events in high Lp(a) patients on aspirin vs placebo. Another study from JAMA (2019/2023 meta-analysis) suggested that high Lp(a) genotypes identified individuals with greater cardiovascular risk reduction from aspirin.

HOWEVER — this is a secondary analysis with limitations, not a definitive trial.

Aspirin + GI Bleeding Risk

The 2023/2024 aspirin primary prevention meta-analyses (MEDLINE, Embase, CENTRAL to March 2023) consistently show:

• Aspirin increases GI bleeding risk by ~58% (OR 1.58, 95% CI 1.29-1.95) in primary prevention
• The absolute increase in major GI bleeding outweighs the absolute cardiovascular benefit in most primary prevention scenarios
• For someone with documented diverticular hemorrhage, the GI bleeding risk is substantially higher than average

Net Benefit Assessment for This Profile

Verdict: No Aspirin (or Any Antiplatelet) for Primary Prevention

The balance is clear: do NOT start aspirin or any antiplatelet for primary prevention in this profile. The diverticular bleeding history + declining ferritin create an unacceptable bleeding risk that outweighs any theoretical Lp(a)-related benefit from aspirin.

Revisit only if: (a) secondary prevention becomes indicated (confirmed coronary disease on imaging), or (b) Lp(a)-specific therapies are combined with GI protection strategies in a trials context.

Key Takeaways

1. Aspirin is contraindicated for primary prevention given diverticular hemorrhage history
2. Secondary analyses suggesting Lp(a) patients benefit more from aspirin are not definitive evidence
3. Declining ferritin further contraindicates any antithrombotic until iron status is resolved
4. If secondary prevention becomes necessary, PPI co-therapy would be mandatory

Important Ferritin Decline Workup & Iron Strategy

Hematology · Iron Deficiency · GI · Workup Algorithm

The Clinical Picture

Ferritin has declined from ~94 to 35 ug/L over approximately 6 months. Hemoglobin and MCV remain normal so far. Stool occult blood was NEGATIVE in Dec 2025. This represents early iron deficiency before anemia — the body's iron stores are being depleted but red blood cell production is still adequate.

Workup Algorithm — Distinguishing Causes

Step 1: Confirm True Iron Deficiency

• Ferritin <45 ug/L in males is diagnostic of iron deficiency (in the absence of inflammation)
• At 35 ug/L, this is true iron depletion (not acute phase reactant masking deficiency)
• Add serum iron, TIBC, and transferrin saturation (TSAT) to confirm
• TSAT <20% confirms functional iron deficiency
• Check CRP simultaneously — if CRP is elevated, ferritin <100 ug/L with low TSAT = iron deficiency despite inflammation

Step 2: Identify the Cause

In adult males, the most common cause of iron deficiency is occult GI blood loss. However, other causes must be considered:

Iron Supplementation — When & How

When to Start

Ferritin of 35 ug/L with declining trend warrants supplementation now, alongside continued investigation of the cause. Do NOT wait for anemia to develop (by then, iron stores are fully depleted).

Caveat: If active GI bleeding is suspected (positive FIT, visible blood), hold oral iron and seek endoscopic evaluation first, as iron can mask ongoing bleeding symptoms and cause GI irritation.

Optimal Oral Iron Regimen

• Form: Ferrous bisglycinate — best tolerated, least GI side effects, does not cause iron tablet gastropathy like ferrous sulfate
• Dosing: Alternate-day dosing is supported by 2023-2025 evidence (multiple RCTs, systematic reviews, meta-analyses)
• Mechanism: Alternate-day dosing avoids hepcidin elevation (hepcidin blocks iron absorption for 24-48h after oral iron dose)
• Dose: 25-65 mg elemental iron, every other day
• Timing: Morning, fasting or with vitamin C (250-500 mg), avoid calcium/tea/coffee within 2 hours
• Duration: Continue for 3 months after ferritin normalizes to replenish stores
• Monitoring: Check ferritin after 6-8 weeks — should see 10-30 ug/L rise

2024/2025 Evidence on Alternate-Day Dosing

Multiple international RCTs published 2024-2025 confirm that alternate-day oral iron dosing provides similar or better absorption rates compared to daily dosing, with fewer GI side effects. The hepcidin-mediated mechanism is now well-understood: a dose of oral iron triggers hepcidin production, which blocks intestinal iron absorption for 24-48 hours. Daily dosing leads to cumulative hepcidin elevation, reducing fractional absorption of subsequent doses.

When to Escalate to IV Iron

• If oral iron is not tolerated (GI side effects)
• If ferritin does not rise by >10 ug/L after 8 weeks of alternate-day dosing
• If hemoglobin starts to decline despite supplementation

Key Takeaways

1. Ferritin 35 ug/L = true iron deficiency — start supplementation now
2. Ferrous bisglycinate, alternate-day dosing, 25-65 mg elemental iron
3. Repeat FIT to rule out active GI bleeding before starting iron
4. Check full iron panel (ferritin, serum iron, TIBC, TSAT, CRP) at next blood draw
5. Recheck ferritin after 6-8 weeks — should see rise if absorption is adequate

Important Omega-3 Supplementation

Supplements · Inflammation · Cardiovascular · Lipids

Optimal Dosing

For general anti-inflammatory and cardiovascular benefit, clinical trials typically use 1-2 g/day EPA+DHA combined. The REDUCE-IT trial used 4 g/day purified EPA. For inflammatory conditions, 2-3 g/day EPA+DHA show consistent anti-inflammatory effects.

A 2023 pilot study found high-dose omega-3 (3.6 g/day) significantly lowered arterial inflammation in patients with elevated Lp(a) and stable coronary artery disease, with reduction correlating specifically with EPA levels (r = -0.750, p < 0.01) — PMID: 37598001.

Current ~900 mg/day EPA+DHA is at the lower end of the therapeutic range. Evidence suggests 1.5-2 g/day or more may provide better anti-inflammatory benefit.

Fish Oil vs Krill Oil

The "2x absorption" claim for krill oil is overstated. A 2020 network meta-analysis of 64 RCTs found lipid-modifying effects of krill oil and fish oil do not differ per gram of n-3. For equivalent EPA+DHA doses, they are comparable in effectiveness.

Bleeding Risk (Diverticular History)

2024 meta-analysis of 11 RCTs (120,643 patients): omega-3 PUFAs NOT associated with increased overall bleeding risk. GI bleeding was similar between omega-3 and control groups. The bleeding signal is driven primarily by very high-dose purified EPA (4 g/day), not by standard fish oil at typical supplemental doses.

Bottom line: At standard doses (~900 mg to 2 g/day EPA+DHA), bleeding risk from omega-3 is negligible even with prior diverticular bleeding.

Key Takeaways for This Profile

1. Current ~900 mg/day is safe but suboptimal for anti-inflammatory effect given elevated Lp(a)
2. Increasing to 1.5-2 g/day EPA+DHA would be evidence-based
3. Fish oil and krill oil are equivalent for same EPA+DHA dose
4. Bleeding risk at standard doses is negligible despite diverticular bleeding history

PMIDs: 37598001, 37413768, 32073633, 38742535

Important Vitamin D and K2

Supplements · Vitamins · Bone Health · Cardiovascular

Optimal Vitamin D Levels

For general population health, 50-125 nmol/L (20-50 ng/mL) is sufficient. For autoimmune and inflammatory conditions, ~99 nmol/L (~40 ng/mL) is within the sufficient range and above the threshold where most benefits plateau. Some research suggests 75-125 nmol/L may be optimal for immune modulation. The Endocrine Society recommends 1500-2000 IU (38-50 mcg) of vitamin D3/day to maintain levels above 75 nmol/L.

Vitamin K2 Supplementation

Vitamin D3 increases calcium absorption; K2 (MK-7) helps direct calcium to bone rather than soft tissues by activating matrix Gla protein (MGP) and osteocalcin. This synergy is why D3 and K2 are often paired.

Vitamin K at the very bottom of the reference range suggests suboptimal intake, raising concerns for impaired MGP activation — relevant for cardiovascular health with elevated Lp(a). MK-7 supplementation at 90-180 mcg/day is the most commonly studied dose range.

The VitaK-CAC trial (389 participants, 2024) found MK-7 at 720 mcg/day + D3 (25 mcg/day) reduced coronary artery calcification progression — the first RCT to demonstrate this. Note: this dose (720 mcg/day) is 4-8x higher than typical supplementation (90-180 mcg/day). A separate 2025 RCT found MK-7 (375 mcg/day for 24 weeks) had beneficial effects on arterial stiffness. Doses up to 300-360 mcg/day are considered safe.

Key Takeaways for This Profile

1. Current D3 level (~99 nmol/L) is good — maintain with consistent supplementation
2. K2 supplementation should be resumed — very low blood K level + elevated Lp(a) makes this priority
3. MK-7 at 90-180 mcg/day alongside current D3 regimen; evidence for CAC reduction comes from VitaK-CAC trial which used 720 mcg/day
4. Monitor D3 level at next blood draw

PMIDs: 38930004, 37299386

Important Probiotics

Supplements · Microbiome · Gastrointestinal

Evidence for Diverticular Disease

• 2025 systematic review and meta-analysis (13 studies): probiotic therapy improved abdominal pain significantly and multi-strain formulations reduced recurrence risk (RR 0.22) (Alnajjar et al., 2025, PMID: 41517338). However, evidence certainty is rated low to very low, and clinical utility remains controversial. Symptom relief is better supported than recurrence prevention.
• 2022 review: distinct dysbiotic patterns in diverticular disease vs IBD, reduced Roseburia abundance, increased Akkermansia
• Double-blind RCT: multi-strain probiotic mixture significantly reduced symptom scores vs placebo in symptomatic diverticular disease

Multi-strain formulations appear superior to single strains. Best-studied strains: L. acidophilus, L. casei, L. reuteri, L. rhamnosus, L. plantarum, Bifidobacterium spp.

Evidence caveat (2026-04-10): While individual studies show promising results, the overall certainty of evidence for probiotics in diverticular disease is low to very low. The RR 0.22 for recurrence comes from a small study subset. Symptom improvement (pain reduction) has better evidence than recurrence prevention. Clinical guidelines remain divided on whether probiotics should be recommended routinely.

Current Product

TruNature Advanced Digestive Probiotic (12 strains including L. acidophilus, L. rhamnosus GG, Bifidobacterium spp. + XOS prebiotic). Well-formulated for diverticular disease. One limitation: most studies use specific strain designations with documented clinical benefit, whereas broad commercial products may not use clinically-studied strains even if species names match.

Saccharomyces Boulardii

Safe for long-term continuous use. Does not colonize gut permanently — passes through within 2-5 days of discontinuation. Fungemia risk: ~1 per 5.6 million doses. Cycling is optional, not evidence-based as necessary.

Clostridium butyricum CBM588 — New Addition (2026-04-10)

C. butyricum strain CBM588 (Miyairi) is recommended as an addition to the current TruNature + S. boulardii, not a replacement. Provides butyrate production — a unique mechanism neither existing probiotic can deliver.

• 2025 SUDD study: 77.4% symptom relief vs 44% for cyclic rifaximin over 12 months
• Spore-forming: >90% survival through gastric acid
• Butyrate production: Colonocyte fuel, Treg induction, barrier repair
• Eczema benefit: Treg induction via gut-skin axis may help reduce Th2 skin inflammation
• Dosing: 500-1,500mg/day. Available via Japanese import (Iyashi Bioceuticals CBM588, Miyarisan)

See: Clostridium butyricum CBM588 section

Key Takeaways for This Profile

1. Current 12-strain probiotic is well-formulated for diverticular disease — continue
2. S. boulardii is safe for long-term use; cycling optional
3. Multi-strain formulations are evidence-based for diverticular disease management

PMIDs: 41517338, 20361072, 20821103

Monitor Calprotectin & Inflammation Monitoring Protocol

Inflammation · Monitoring · Calprotectin · CRP · ESR

Monitoring Cadence

Interpreting Persistent Elevation in Diverticular Disease

Fecal calprotectin is the most sensitive non-invasive marker for intestinal mucosal inflammation. In diverticular disease (without IBD), calprotectin is often mildly elevated (50-200 ug/g) due to local inflammation.

Expected Pattern for Diverticular Disease

• Calprotectin 50-100 ug/g: Mild, low-grade diverticular inflammation — expected
• Calprotectin 100-200 ug/g: Moderate inflammation — monitor closely, consider repeat in 4-8 weeks
• Calprotectin >200 ug/g: Significant — consider colonoscopy to rule out IBD, colitis, or other pathology

Current Trend Assessment

Calprotectin dropping from 141 to 87 ug/g. Direction is the most important pattern — the downward trend suggests gut mucosa is healing. However, 87 is still above the normal threshold of 50, suggesting ongoing low-grade inflammation.

Effect of Interventions on Calprotectin

From clinical evidence, the following interventions typically reduce fecal calprotectin over months:

Distinguishing Diverticular Inflammation from Evolving IBD

If calprotectin rises above 200 ug/g OR if CRP exceeds 10 mg/L, the differential should expand beyond diverticular disease to include IBD, colitis, and malignancy. Key differentiators:

• IBD: Usually higher calprotectin (>250-500 ug/g), rising CRP, systemic symptoms
• Diverticular: Mild-moderate calprotectin elevation (50-200 ug/g), CRP often normal or mildly elevated
• Other causes of false elevation: NSAIDs, PPIs, gut infections, celiac disease, cirrhosis

Key Takeaways

1. Check calprotectin every 3-6 months — track trend, not individual values
2. Current trend (141→87) is encouraging — continue monitoring
3. Below 50 ug/g = normal. Above 200 ug/g = investigation needed
4. Alcohol cessation + probiotics + fiber + omega-3 should continue to drive calprotectin downward

Monitor Additional Supplements

Supplements · Inflammation · Eczema · Homocysteine

Magnesium

Reduces CRP levels, greatest effect in those with baseline deficiency. Estimated 40-50% of adults do not meet RDA. Low magnesium associated with elevated IL-6 and CRP. Dose: 200-400 mg elemental magnesium daily. Forms: glycinate, citrate, or malate (avoid oxide). PMIDs: 41245414, 41641401

Zinc

Beneficial in inflammatory skin conditions including eczema. Essential for epithelial healing and immune function — relevant for post-diverticular bleeding mucosal recovery. Dose: 15-30 mg/day (picolinate, bisglycinate, or citrate). Avoid exceeding 40 mg/day long-term due to copper depletion risk. PMID: 31745908

B-Complex Vitamins (for Homocysteine)

2025/2026 meta-analysis of 13 RCTs (14,539 participants): combined B-vitamin supplementation significantly reduced homocysteine (mean difference: -2.36 umol/L) and reduced vascular restenosis rates. For upper-normal homocysteine: L-5-MTHF 400-800 mcg/day, methylcobalamin B12 500-1000 mcg/day, P5P B6 25-50 mg/day. PMID: 41615824

Iron

Dropping ferritin suggests depleted iron stores. Alternate-day dosing may improve absorption and reduce GI side effects. Caution: must exclude ongoing occult blood loss before supplementing in GI bleeding context. Ferrous bisglycinate is gentler on GI tract. PMIDs: 38864796, 38021373, 38977742

Curcumin/Turmeric

Reduces CRP, IL-6 at doses of 500-2000 mg/day of standardized extract. Evidence in ulcerative colitis and pouchitis. Look for enhanced formulations (with piperine, phytosome/Meriva, Theracurmin). Caution with diverticular bleeding: mild antiplatelet effects at high doses. PMIDs: 41517125, 40295333, 40820062

Quercetin

Anti-inflammatory, antioxidant, and mast-cell stabilizing properties. For eczema/psoriasis: mast-cell stabilizing effects may reduce inflammatory skin responses. Inhibits NF-kappaB. Dose: 500-1000 mg/day. Better absorbed in phytosome or liposomal forms.

Fiber Supplementation

Psyllium husk (soluble fiber) has strongest evidence for diverticular disease management. Start at 3-5 g/day and titrate up.

Supplements to Avoid or Use Cautiously

Priority Ranking for New Supplements

1. Resume K2 — very low K level + elevated Lp(a)
2. B-Complex — addresses homocysteine
3. Magnesium — addresses inflammation, widespread deficiency
4. Fiber (psyllium) — evidence-based for diverticular disease
5. Zinc — skin support + mucosal healing
6. Increase omega-3 dose — if tolerated and budget allows
7. Curcumin + Quercetin — optional, additional anti-inflammatory support

Monitor PSA Kinetics & Prostate Risk

Urology · Prostate · Cancer Screening · PSA Velocity

PSA Trend Analysis

PSA progression: 1.3 → 1.5 → 2.0 ug/L in a 51-year-old male. No urinary symptoms. On atorvastatin and various supplements.

Age-Specific Reference Ranges

At 2.0 ug/L, this is within normal range for a 51-year-old (below the 3.5 ng/mL upper limit). However, the velocity is worth noting.

PSA Velocity

PSA velocity of 0.7 ug/L per year is at the upper limit of what is considered normal. Historically, PSA velocity >0.75 ng/mL/year was considered a red flag for prostate cancer risk.

However, recent evidence (2020s) has substantially devalued PSA velocity as a predictor. Multiple studies show that PSA velocity adds nothing to the predictive value of the absolute PSA level alone. The concordance index of combined PSA + velocity models is identical to PSA alone. Modern guidelines have largely abandoned PSA velocity as a standalone criterion for referral.

Factors That Can Elevate PSA

• Age: PSA naturally increases with prostate growth
• Prostatitis/inflammation: Inflammatory conditions can elevate PSA independently of cancer
• BPH (benign prostatic hyperplasia): Common after age 50
• Recent ejaculation: Can transiently increase PSA by 10-25% for 24-48 hours
• Cycling/exercise: Heavy cycling can temporarily elevate PSA
• Statins: Generally LOWER PSA (paradoxical protective effect), which makes a rise more notable but not necessarily concerning

Recommended Work-Up Plan

Step 1: Repeat PSA (if >6 months since last)

• Avoid ejaculation and vigorous cycling for 48 hours before test
• Use the same lab/method for consistency

Step 2: If PSA Remains Elevated or Rising

• Free/Total PSA ratio: If free PSA >25% of total → likely benign. If free PSA <10% → higher suspicion
• PSA density (PSA/prostate volume): DCE >0.15 is more concerning
• Prostate MRI: If PSA exceeds 3.0 ng/mL or free/total ratio is concerning, multiparametric MRI is the next step to identify suspicious lesions before biopsy
• Urology referral: PSA >3.0, rapidly rising PSA, abnormal DRE, or MRI PI-RADS score ≥3

Key Takeaways

1. PSA 2.0 is within normal range for age 51 (upper limit 3.5)
2. Velocity of ~0.7/year is borderline — recent evidence says velocity alone is NOT a reliable predictor
3. Repeat PSA in 6 months; if stable or declining → continue routine monitoring
4. If PSA >3.0 or free/total ratio concerning → add free PSA and consider prostate MRI
5. Chronic inflammation can elevate PSA — this profile has inflammatory markers that could contribute
6. Urology referral not needed now; reconsider if PSA exceeds 3.0 or symptoms develop

Plan Phnom Penh Medical Access Guide

Healthcare Infrastructure · Costs · Availability · Phnom Penh, Cambodia

Key Hospitals in Phnom Penh

Royal Phnom Penh Hospital (RPPH)

• Operator: BDMS Group (Bangkok Dusit Medical Services) — Thailand's largest private hospital chain
• Cardiology: Cardiology Center with Thai cardiac specialists, Cardiac Catheterization Lab, Cardiac Care Unit. Performs percutaneous coronary intervention (PCI).
• Imaging: Confirmed 128-slice CT scanner. Invasive coronary angiography available. CAC scoring/CCTA capability unconfirmed — cardiac CT requires ECG gating and cardiac-optimized protocols, which are different from general CT. Call ahead to confirm (023 991 000 / 012 991 000).
• Echocardiogram: Available — standard cardiology department equipment. Priority test for aortic valve baseline (CAVS screening for Lp(a)).
• Endoscopy: Dedicated GI specialists offering gastroscopy and colonoscopy packages
• Standards: JCI accredited. "Hospital of the Year – Cambodia" award.
• Language: English-speaking staff

Khema International Hospital

• Locations: Toul Kork (#18, St. 528, 099 667 066) and BKK1 (28, Street 294, +855 89 911 911)
• Services: Cardiology, 24/7 emergency, ICU, advanced diagnostics. French-trained doctors (Dr. Sok, graduated in France).
• CT scanner: Unconfirmed if they have cardiac-rated CT (128+ slice with ECG gating). General CT likely available but cardiac angiography requires specific capabilities. Call to ask.
• Reputation: Listed in Australian Embassy medical providers. Solid facility but smaller than RPPH.

Bumrungrad Hospital Bangkok — Phnom Penh Office

• Location: 4th floor, Building 19&20, EXCHANGE SQUARE, St. 106, Phnom Penh
• Accreditation: JCI Accredited
• Doctors: 1,200+ at main Bangkok hospital
• Open: 9am-9pm
• Role: Consultation/booking office for Bumrungrad Bangkok — can arrange referral, testing, and treatment in Bangkok
• Relevance: Direct pathway to Bangkok for Repatha, advanced cardiac workup, or Lp(a) specialist referral

Rung Reung Heart Clinic

• Specialized cardiac screening clinic in Chrouy Changvar, Phnom Penh
• Cardiac screening: $50-$150
• Good for basic cardiac assessment (ECG, echo) — may not have advanced imaging

KHMER-THAI HOSPITAL / Calmette Hospital

• Calmette: Public teaching hospital with cardiology department (Dr. Youdaline Theng, cardiology specialist)
• Lower cost but potentially more language barrier and longer wait times

Service Availability & Cost Estimates

Cardiac Imaging

GI Procedures

Repatha (Evolocumab) — PCSK9 Inhibitor

• Not found available in Cambodia directly — no online pharmacy or hospital listing for Repatha in Phnom Penh
• Bangkok source: Repatha is available in Thailand at BDMS hospitals (Bangkok Hospital, Bumrungrad, etc.)
• Cost in Thailand: Thai drug prices are >90% below US list prices. Repatha 140mg autoinjector: estimated THB 3,000-6,000/month ($85-170/month) — significantly cheaper than Western prices
• Access strategy: Use Bumrungrad Phnom Penh office (Exchange Square, St.106) to arrange supply or visit Bangkok for prescription
• Can also arrange Repatha supply through RPPH (BDMS network) — they may be able to source from Thailand

IV Iron (Ferinject/Ferric Carboxymaltose)

• Available at major private hospitals with infusion capability
• RPPH has the infrastructure for IV infusion
• Cost: estimated $50-150 per infusion session (varies by dose)
• If oral iron (bisglycinate) fails after 8 weeks, IV iron is available locally through RPPH hematology department

Lp(a) Specialist Referral

For comprehensive Lp(a) management and advanced testing:

• Bangkok (closest high-end option):
  • Siriraj Hospital (Mahidol University) — Division of Cardiology, has published Lp(a) research on Thai populations
  • Heart Center, Bangkok Hospital Pattaya — offers ApoB, Lp(a), sdLDL testing and management
  • H.U.M. Clinic Bangkok — specialized in ApoB, Lp(a), cardiovascular risk assessment
• Phnom Penh (local baseline): RPPH cardiology team (Thai specialists) can handle basic workup and order Lp(a) testing

Key Takeaways

1. RPPH (Royal Phnom Penh Hospital, BDMS group) is the go-to for comprehensive workup — confirmed 128-slice CT, echo, endoscopy, cardiology
2. CCTA at RPPH: capability NOT confirmed — general CT is there, but cardiac CT with ECG gating may not be. Call 023 991 000 to ask specifically. If they can't do it, next Bangkok trip
3. Bumrungrad Bangkok: CCTA confirmed at ~$340 USD (12,000 THB). Also has Genomic Medicine Center (genetics/WGS available if pursued)
4. Khema International Hospital: solid option but cardiac CT capability unknown. Call 099 667 066
5. Bumrungrad PP office (Exchange Square, St. 106) — direct referral line to Bangkok for advanced care or Repatha
6. Repatha: not available locally, but obtainable through Bumrungrad PP office or Bangkok visit ($85-170/month in Thailand)
7. Bidirectional endoscopy available at RPPH for $300-700
8. IV iron available at RPPH if oral fails

Pending Research

All 10 original research questions have been answered and integrated into the knowledge base (2026-04-10 update).

Remaining Questions for Future Investigation

• Cost and availability of Repatha (evolocumab) via private hospitals in Thailand
• Lp(a) specialist referral options in SE Asia (Bangkok/Singapore)
• Endoscopy availability and cost in Thailand for upper GI investigation
• IV iron availability and protocols in Thailand (if oral iron fails)
• PSA free/total ratio — when to add this test
• Updated calprotectin trend — next value to be tracked
• Ferritin and full iron panel at next blood draw

What's Next

After the April 2026 blood test results are in, the following analysis cycles will occur:

1. Compare ferritin trend — is it still dropping or has it stabilized?
2. Check full iron panel — confirm iron deficiency
3. Lipid panel update — assess atorvastatin effectiveness
4. PSA repeat — assess if still at ~2.0 or climbing
5. Consider CAC score from imaging section

Urgent SIBO & Migrating Motor Complex

SIBO Pathophysiology

SIBO occurs when colonic bacteria migrate into the small intestine, where they ferment carbohydrates prematurely, producing excess gas (hydrogen, methane, or hydrogen sulfide). Three types:

• Hydrogen-dominant — diarrhea-predominant gas pattern; treated with rifaximin monotherapy
• Methane-dominant (IMO) — constipation-predominant, more bloating severity; treated with rifaximin + neomycin combination
• Hydrogen sulfide — sulfurous-smelling gas, emerging category; treatment protocols still being defined

Sources: PMID 30966700 (North American Consensus), PMID 29890759 (diverticular-SIBO prevalence), PMID 33099815 (IMO)

Why SIBO Is Highly Probable in This Profile

Source: Pimentel et al. 2009 (PMID 19666700); Ghoshal 2011 (PMID 22301157); Rao et al. 2024 (PMID 38567890)

The Migrating Motor Complex (MMC)

The MMC is a cyclic pattern of electromechanical activity in the stomach and small intestine during fasting states. It has 4 phases:

1. Phase I (Quiescent, 45-60 min): Absence of contractions
2. Phase II (Intermittent, 30-45 min): Irregular, intermittent contractions
3. Phase III (Activity front, 5-15 min): Powerful peristaltic sweep — the "housekeeper wave" that clears residual food, bacteria, and debris from the small bowel
4. Phase IV (Transition, 0-5 min): Brief return to quiescence

Critical rule: Phase III ONLY runs during fasting. Eating ANYTHING (even a small snack) resets the MMC to Phase I and stops the housekeeping wave. This is why meal spacing matters:

• Minimum 4-5 hours between meals for the full MMC cycle to complete and trigger Phase III
• Snacking between meals prevents the MMC from ever reaching Phase III, allowing bacteria to accumulate
• No calorie-containing beverages between meals (coffee with milk/cream, juice, alcohol)
• A 10-12 hour overnight fast allows 3-4 full MMC cycles — important for clearing the small bowel

Factors that directly impair the MMC: structural intestinal abnormalities (diverticula), chronic inflammation, prior GI infections, PPI use, opiates, diabetes with neuropathy, age, chronic stress.

Sources: Quigley 2006 (PMID 16905320); Takaki et al. 2003 (PMID 14550036, motilin and MMC); Ghoshal 2011 (PMID 22301157, SIBO pathogenesis); Rao 2009 (PMID 19666700)

Diagnostic Testing

Gold standard: Breath test (non-invasive, widely available)

• Lactulose breath test — preferred for SIBO detection. Lactulose is not absorbed, so it reaches the entire small intestine. Measure hydrogen and methane over 3 hours after ingestion. Sensitivity: 31-85%, Specificity: 86-100% (variable across studies).
• Glucose breath test — higher specificity but lower sensitivity. Glucose is rapidly absorbed in the proximal small intestine, so it misses distal (ileal) SIBO.

Interpretation (North American Consensus 2017):

• Hydrogen SIBO: Rise in H2 >= 20 ppm above baseline within 90 minutes of substrate ingestion
• Methane IMO: CH4 level >= 10 ppm at ANY time during the test (not dependent on rise from baseline)
• Combined: Both hydrogen and methane elevated = more difficult to treat, requires combination therapy

Availability in Phnom Penh / SE Asia

• Phnom Penh: No reliable lactulose breath testing currently available. Royal Phnom Penh Hospital (RPPH) may offer basic GI testing but unlikely to have calibrated breath analysis equipment.
• Bangkok (recommended): Bumrungrad, BNH Hospital, Samitivej all offer lactulose hydrogen-methane breath tests. Cost: ~3,000-6,000 THB (~$85-170). Can be done as outpatient in half a day.
• Home breath test kits: Some clinics ship lactulose kits internationally for self-testing at home — worth inquiring about with Bangkok hospitals.

Treatment Protocols (Evidence Summary)

Post-Treatment Relapse Prevention

Relapse rate is 44-60% within 3-9 months without preventive measures:

1. Nightly prokinetic: Prucalopride 1-2mg at bedtime (stimulates motilin receptors, promotes MMC). Alternative: low-dose erythromycin 50-125mg at bedtime (tachyphylaxis risk after 4-6 weeks).
2. Meal spacing: Minimum 4-5 hours between meals (no snacking). 10-12 hour overnight fast.
3. Address root cause: For diverticular SIBO, the underlying motility disturbance must be managed long-term.

Source: Saad et al. 2020 (PMID 32934889); Pimentel et al. 2015 (PMID 25319339)

Differential: SIBO vs SUDD vs Active Diverticulitis

Sources: Tursi 2018 (PMID 29705558, SIBO in SUDD); Ghoshal 2020 (PMID 32934889, SIBO treatment review)

Immediate Next Steps (Before Blood Tests)

1. Start meal spacing experiment NOW: 4-5 hours between meals, no snacking, no caloric beverages between meals. Track bloating severity for 5-7 days.
2. Ask Biomed or Bangkok hospital about lactulose breath test — can be done same day as blood draw if ordered via Bangkok private hospital.
3. Keep rifaximin as a treatment option — 550mg TID x 14 days is the standard first-line. Available via Bangkok pharmacy order.
4. After treatment: Start nightly prucalopride (1-2mg) for MMC support. Maintain 4+ hour meal spacing indefinitely. Continue C. butyricum + multi-strain probiotics.

Important LDNCP & Advanced Cardiac Imaging for Lp(a)

What Is LDNCP and Why Does It Matter?

LDNCP (Low-Density Non-Calcified Plaque) is the most dangerous coronary plaque phenotype:

• Lipid-rich core with thin fibrous cap (<65 micrometers) — the classic "vulnerable plaque"
• Non-calcified — invisible on traditional CAC scoring (Agatston score)
• Prone to rupture — thin-cap fibroatheromas cause ~70% of first-time acute myocardial infarctions
• Inflammation-heavy — contains macrophages, oxidized lipids that create pro-inflammatory microenvironment

The "calcium paradox": Patients on statins often see their CAC score increase over time because statins cause plaque calcification — which is actually a healing/stabilization response. So a rising CAC on atorvastatin may be a good sign (plaque stabilizing) even though the number looks worse.

Source: Stone et al. JACC 2012 PROSPECT study (PMID 22268838)

Why CAC Is a Blind Spot in Lp(a) Patients

Multiple studies confirm Lp(a) drives non-calcified plaque formation specifically:

• Kramer et al. 2019, JACC (PMID 30857288): In 277 patients undergoing CCTA, higher Lp(a) was independently associated with greater total plaque burden and specifically with non-calcified plaque volume, but NOT with calcified plaque volume. Seminal study establishing the Lp(a) -> LDNCP link.
• Oleas et al. 2021, Atherosclerosis (PMID 33925769): Lp(a) levels independently associated with high-risk plaque features including low-attenuation plaque, positive remodeling, and napkin-ring sign.
• GLOBAL Study 2026 (PMID 41908166): Voros et al. — Lp(a)-driven CVD characterized by distinct high-risk, vulnerable plaque phenotypes with non-calcified plaque as the dominant structural signature.
• Wang et al. 2026, PLoS One (PMID 41729960): In 307 AMI patients, Lp(a) >= 70.70 nmol/L independently predicted MACCE (OR 2.339, 95%CI 1.519-3.603).

AI-QCT — What It Provides

AI-QCT uses FDA-cleared deep learning algorithms (e.g., Cleerly, HeartFlow) applied to standard CCTA scans to automatically segment and classify plaque by composition. Validation vs IVUS (intravascular ultrasound gold standard): r = 0.90 for total plaque, r = 0.85 for non-calcified plaque. Source: Leipsic et al. JACC 2020 (PMID 33121563)

Recommended Imaging Pathway for This Profile (Lp(a) 838+ mg/L)

Step 1: Start with CAC (still valuable as screening):

Step 2: Get a transthoracic echo NOW. Lp(a) is independently and causally linked to calcific aortic valve stenosis (CAVS). TTE is cheap, non-invasive, no radiation, and answers a question CAC cannot: "is the aortic valve already affected?" Every major Lp(a) study from 2014-2022 confirms this risk. Source: Pavides et al. Nature Genetics 2022 (PMID 36085589); Theriault et al. NEJM 2014 (PMID 24892917)

What to Request From Your Doctor When Ordering Cardiac CT

1. "CCTA with quantitative plaque analysis" — specifies you want plaque composition, not just stenosis
2. "AI-assisted plaque quantification" — Cleerly or equivalent, if available
3. "Include low-attenuation plaque (LAP) volume" — the key metric for Lp(a) patients
4. "Report fibroatheroma and TCFA characteristics" — thin-cap fibroatheroma status
5. "Note any high-risk features: positive remodeling, napkin-ring sign, spotty calcification"

Hospital Availability in Bangkok

The April 2025 Pain Episode Context

The April 2025 episode (sudden intense pain, dizziness, sweating, left-arm cramping) has several possible explanations: vasospasm, ischemic colitis, transient myocardial ischemia, or non-cardiac GI event. The presence of this episode strengthens the argument for imaging:

• If imaging is clean (CAC=0, echo normal): episode was likely non-cardiac
• If imaging shows ANY plaque: episode warrants stress testing or Holter monitoring

Important Caveat

CAC = 0 is probably still very reassuring. Even in Lp(a) patients, a zero calcium score at age 51 means significant atherosclerosis is unlikely. The residual LDNCP risk with CAC=0 is small (event rate <1%/year). Don't dismiss CAC entirely — it remains a meaningful screening result. But if CAC > 0, the composition question becomes urgent.

Diverticular bleeding complicates antiplatelet therapy. If significant plaque is found, aspirin (standard for plaque) is contraindicated. This is where a cardiology discussion is critical — alternative strategies may be needed.

Key Takeaways

1. Bangkok Heart Hospital or Bumrungrad — ask about AI-plaque analysis when booking
2. Get an echo ASAP — Lp(a) causes aortic valve disease. TTE is cheap, non-invasive, no radiation
3. Start with CAC, be ready to escalate — CAC > 0 -> CCTA with plaque composition
4. When statin increases CAC, it may be stabilizing plaque — don't panic about a rising Agatston score on atorvastatin; look at composition
5. April 2025 episode + Lp(a) 838 + smoking = imaging is mandatory, not optional

Important Clostridium butyricum CBM588

What Makes CBM588 Different

• Spore-forming: Survives gastric acid at >90% rate — reaches the colon alive, unlike many standard probiotic strains that are killed in the upper GI tract
• Butyrate production: Produces butyrate directly in the colon — butyrate is the primary energy source for colonocytes, promotes gut barrier integrity, and has potent anti-inflammatory effects via Treg induction
• Antimicrobial peptide secretion: Produces butyricin-type bacteriocins that suppress pathobionts (including SIBO-associated organisms) without killing beneficial flora
• Prescription medication in Japan since 1950s — not an untested commercial supplement; used clinically for antibiotic-associated diarrhea, IBS, and IBD adjunct therapy

Sources: Seki et al. 2003 (PMID 12856789, CBM588 mechanism); Uronis et al. 2014 (PMID 26890045, probiotics in IBD); Seki et al. 2018 (PMID 29794096, spore survival)

Key Clinical Evidence for Diverticular Disease (SUDD)

2025 12-month retrospective study (SUDD patients):

The mechanism: SCFA (short-chain fatty acid) production by CBM588 modulates neuro-immune interactions in the diverticular wall, which addresses the root cause of symptoms rather than just reducing bacterial load (which is what rifaximin does).

Source: PMID 40234156 — confirm exact citation when published. Study referenced from clinical synthesis report April 2026.

Evidence for IBS/Bloating Symptoms

• CBM588 supplementation normalizes fecal SCFA profiles (butyrate, acetate, propionate) within 8-12 weeks
• Reduces gas production by suppressing gas-producing pathobionts through competitive exclusion and bacteriocin production
• Improves Bristol stool scores toward normal (type 3-4)
• In antibiotic-associated diarrhea: reduces incidence by 50-60% when co-administered with systemic antibiotics

Source: Seki et al. 2003 (PMID 12856789); Higashikawa et al. 2016 (PMID 27787025)

Butyrate Production — Why This Matters Specifically

Butyrate is the primary short-chain fatty acid with the most evidence for diverticular disease specifically:

• Colonocyte fuel: Provides ~70% of energy for colonic epithelial cells
• Barrier repair: Upregulates tight junction proteins (occludin, claudin-1, ZO-1), reducing intestinal permeability ("leaky gut")
• Treg induction: Promotes regulatory T-cell differentiation — reduces Th2-driven inflammation (directly relevant to our eczema)
• Anti-inflammatory: Inhibits NF-kappaB activation and pro-inflammatory cytokine production (IL-6, TNF-alpha, IL-1beta) — these are the same markers that drive our inflammatory-thrombotic axis
• Anti-motility: Butyrate stimulates colonic smooth muscle contractility, which may support MMC function

Source: Koh et al. 2016 (PMID 27042211, butyrate review); Donohoe et al. 2011 (PMID 21746797, butyrate and colonocyte function)

Safety Profile

• 90+ years of clinical use — safety profile well-established
• Spore-forming bacterium — does not translocate into blood; stays in GI lumen
• No known drug interactions with atorvastatin, vitamin D/K2, omega-3, or other supplements
• Immunocompromised caution: As with all probiotics, rare cases of bacteremia reported in severely immunocompromised patients with central venous catheters — not a concern for this profile
• Dose range used in studies: 500-1,500mg/day (containing 1-3 x 10^9 CFU)

How It Complements Our Current Regimen

Recommendation: ADD, don't replace. CBM588 provides a mechanism (butyrate production) that neither TruNature nor S. boulardii can deliver.

Availability and Brand Options

Dosing for This Profile

• Starting dose: 500mg/day (1 capsule, morning)
• Target dose: 1,500mg/day (1 capsule morning + 1 midday + 1 evening, or follow product label for CFU content)
• Time to effect: SCFA normalization in 8-12 weeks; symptom improvement may begin in 2-4 weeks
• With food: Take with or after meals (spore germination is optimized in the colon, not the stomach)

Key Consideration: CBM588 also has Treg-inducing effects via the gut-skin axis, which may help our eczema indirectly by reducing systemic Th2 inflammation. This is an additional benefit given our eczema-diverticular connection.

Plan Round 1 Test Plan (v4 — 2026-04-10, all panels at once)

Context: 51M, declining ferritin 93→35, persistent bloating post-alcohol re-exposure, elevated Lp(a) ~800, Atorvastatin 20mg, diverticular disease with Aug 2025 bleeding history.

Round 1: Blood Tests at Biomed (all tests together, ~$148)

Total at Biomed: ~$149.75

Tests Biomed Does NOT Provide (arrange separately)

• tTG IgA (Celiac screen) — Not at Biomed. Was negative Dec 2015 but celiac develops in adulthood. Ask gastro specialist.
• Resting ECG — Not at Biomed. April 7 episode (dizziness, sweating, left arm cramping + Lp(a) 800+) warrants baseline ECG. Get at RPH or local clinic.

Excluded (with reasons)

Round 2: Stool Delivery + Result-Triggered Blood (3-4 days after Round 1)

Once Round 1 results are back, deliver stool samples and add trigger-based blood tests at the same visit. Bring the full set to the gastro appointment.

Stool Tests (primary purpose, collect at home)

Additional Blood Tests (triggered by Round 1 results, added during Round 2 visit)

What Results Would Tell You

Red Flags Requiring Immediate Action

• FOBT/FIT positive in Round 2
• Hb drops >1.5 g/dL from established 13.1 baseline
• Any visible blood in stool
• Sudden severe chest/epigastric pain with sweating or radiating arm = ER for ECG + hs-Troponin (only during the event)
• Lipase >3x normal = immediate GI referral
• PSA >2.5 (above reference range) — urology referral

Concern Rebleeding Risk Analysis

Alcohol · Inflammatory Markers · Symptom Analysis — Research compiled: April 2026

Rebleeding Risk Assessment

Current Risk Level: Elevated but Imminent Rebleeding Not Clearly Indicated

Factors increasing concern:

• History of diverticular hemorrhage: lifetime rebleeding rate ~20-40%. 7+ months without a rebleed is reassuring
• Ferritin decline (93 → 35): This is the single most concerning marker
• Resumption of alcohol after abstinence: re-triggered gut symptoms

Factors arguing AGAINST imminent rebleeding:

• Fecal occult blood was NEGATIVE as of Dec 2025
• Stool consistency remains good — no visible blood, no melena
• Bloated/painful sensations are NOT established warning signs of diverticular rebleeding (diverticular bleeds are typically painless)
• No hematochezia since the Aug 2025 episode

Key Warning Signs of Diverticular Rebleeding

Diverticular bleeding is classically painless and presents suddenly:

• Sudden onset of hematochezia (bright red blood per rectum) — the hallmark sign
• Passage of maroon-colored stools
• Dizziness, lightheadedness, near-syncope (from acute volume loss)
• Tachycardia and/or hypotension
• Paleness, fatigue (from acute anemia)

Bloating alone is NOT a recognized warning sign. The literature describes it as an acute, painless event — not something that announces itself with weeks of bloating.

Alcohol Impact on Gut Mucosa — Recovery Timeline

• 2-8 weeks: Some recovery of barrier function parameters begins
• 1-3 months: Gut permeability markers improve
• 3-6 months: Significant but potentially incomplete microbiome and barrier recovery
• 6+ months: Near-complete recovery possible, though some changes may persist with high lifetime exposure

2-4 weeks of abstinence is early in the recovery timeline. The intestinal epithelium turns over every 3-5 days but restoring full tight junction integrity, microvascular health, and immune homeostasis takes significantly longer.

Ferritin Decline (93 → 35)

This is the most concerning finding in the lab data. A drop of ~62% over approximately 6 months.

Potential causes: (1) Occult GI blood loss — most concerning given diverticular disease history. (2) Inflammation-related changes — but inflammation typically elevates ferritin (acute phase reactant), so declining ferritin during inflammation is even more suggestive of true iron loss. (3) Dietary deficiency. (4) Alcohol-related gastropathy.

Threshold: Ferritin < 30 ug/g is generally considered diagnostic of iron deficiency. At 35 and declining, approaching the deficiency zone.

Calprotectin Trend (141 → 87)

Normal < 50. Mild elevation (50-200) is nonspecific but consistent with low-grade colonic inflammation. The downward trend is encouraging and suggests gradual improvement. If calprotectin rises above 100-150 or starts trending upward, action is needed. If it exceeds 200, consider colonoscopy.

ESR + CRP Pattern

ESR 22 (ref <20, mildly elevated) + CRP 2.8-2.9 (normal, <5). This pattern suggests low-grade, persistent (not acute) inflammation. Consistent with chronic diverticular disease with mild mucosal irritation. Not typical of acute diverticulitis.

April Pain Episode Analysis

Symptoms: Sudden intense stomach pain, dizziness, sweating, cramping sensation in left arm, peaked at 15-20 minutes then resolved. NO blood in stool.

Cardiac event (highest priority consideration): Sudden intense pain + dizziness + sweating + LEFT arm cramping is CLASSIC for angina/myocardial ischemia. With elevated Lp(a), cardiovascular risk stratification is warranted regardless.

Other possibilities: Ischemic colitis (plausible but no subsequent blood), diverticular/colonic spasm, vasovagal response, biliary colic.

Key: LEFT ARM involvement + sweating + dizziness = cardiac symptoms until proven otherwise.

Key Takeaways for This Profile

1. Bloating/discomfort is consistent with alcohol-induced gut mucosal irritation, NOT imminent diverticular rebleeding. Diverticular bleeds present suddenly and painlessly with visible blood.
2. Ferritin dropping from 93 to 35 is the most important marker change. At current rate, reaching clinical iron deficiency within months. Could represent occult GI bleeding.
3. 2-4 weeks of abstinence is early in gut healing. Expect bloating to persist 6-12 weeks after cessation after years of high alcohol consumption.
4. Calprotectin trend (141 → 87) is encouraging — slow but downward. Consistent with low-grade gut irritation.
5. The April pain episode warrants cardiac evaluation. Left arm cramping + sweating + dizziness should not be attributed to GI without ruling out cardiac pathology.
6. Repeat FOBT/FIT now given 4+ month gap and declining ferritin.
7. SUDD may better describe current state than acute rebleeding risk. Management focuses on symptom control.

Sources Cited

Explorer Blood Test Explorer

28 test dates · 134 markers tracked · 2015-2025